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Abstract 
Objective: The aim of this service evaluation was to explore the effectiveness of a psychotherapeutic 
treatment for patients with epilepsy based on the Acceptance and Commitment Therapy (ACT) 
approach and to assess whether this treatment is likely to be cost-effective.  
Method: We conducted an uncontrolled prospective study of consecutive patients with refractory 
epilepsy referred for outpatient psychological treatment to a single psychotherapist because of 
emotional difficulties related to their seizure disorder. Participants were referred by consultant 
neurologists, neuropsychologists or epilepsy nurses and completed a set of validated self-report 
questionnaires (Short Form -12 Version 2, Generalised Anxiety Disorder - 7, Neurological Disorders 
Depression Inventory for Epilepsy, Work and Social Adjustment Scale, and Rosenberg Self-Esteem 
Scale) at referral, the end of therapy and six months post therapy. Patients received a maximum of 
20 sessions of one-to-one psychological treatment supported by a workbook. Cost-effectiveness was 
estimated based on the calculation of quality-adjusted life year (QALY) gains associated with the 
intervention. 
Results: Sixty patients completed the pre- and post-psychotherapy questionnaires, 41 also provided 
six-month follow-up data. Patients received six to 20 sessions of psychotherapy (mean = 11.5, S.D. = 
9.6). Psychotherapy was associated with significant medium to large positive effects on depression, 
anxiety, quality of life, self-esteem, work and social adjustment (Ps < .001), which were sustained six 
months after therapy. The mean cost of the psychotherapy was £445.6 and, assuming that benefits 
were maintained for at least six months after the end of therapy, the cost per QALY was estimated 
to be £11,140 ( ? ? ? ? ? ?9, $18,016; the cost per QALY would be half this amount if the benefits lasted 
one year). 
Conclusion: The findings of this pilot study indicate that the described psychotherapeutic 
intervention may be a cost-effective treatment for patients with epilepsy. The results suggest that 
randomised controlled trial of the psychotherapy programme is justified.  
 
Keywords: Psychotherapy; Refractory epilepsy; Depression; Anxiety; Quality of Life; Self-esteem 
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1. Introduction 
Epilepsy is defined by recurrent epileptic seizures. However, seizures are not the only source of 
disability in patients with this disorder. Epilepsy is associated with an increased risk of cognitive 
deficits (especially memory problems), and rates of mood and anxiety disorders which are two or 
three times higher than in the general population [1].  The initial diagnosis of epilepsy can cause 
adjustment disorders, refractory epilepsy can challenge coping resources, and epilepsy can give rise 
ƚŽƐƉĞĐŝĨŝĐĂŶǆŝĞƚŝĞƐĂďŽƵƚƐĞŝǌƵƌĞƐ ?ǁŚŝĐŚŵĂǇĐĂƵƐĞƐŝŐŶŝĨŝĐĂŶƚƌĞƐƚƌŝĐƚŝŽŶƐŽĨƉĂƚŝĞŶƚƐ ?
independence and social functioning [2-4]. Having epilepsy is associated with perceived stigma, 
especially in the presence of comorbid mood disorders and low self-esteem [5, 6].  This means that 
there are many aspects of living with epilepsy, which could be considered targets for psychological 
treatment. However, access to psychological treatments, specifically designed to address the 
concerns of people with epilepsy, appears to be the exception rather than the rule, although in the 
United Kingdom (UK) national epilepsy treatment guidelines state that psychological treatment 
should be available to all patients with complex or refractory epilepsy [7].  Many of the psychological 
treatments which have been developed for patients with epilepsy have focussed on the attainment 
of seizure control [8], a therapeutic target perhaps better achieved by other means.  
To date it has been relatively easy for healthcare purchasers to ignore references to the provision of 
psychological treatments in epilepsy treatment guidelines because there is insufficient evidence for 
the effectiveness of such interventions [9, 10]. A Cochrane review concluded that many studies were 
of poor methodological quality and yielded contradictory results. More specifically, the review found 
no evidence that relaxation therapy, cognitive behaviour therapy, electroencephalographic (EEG) or 
galvanic skin response biofeedback used alone or in combination had an impact on seizures or 
quality of life. They acknowledged that educational interventions showed greater promise in terms 
of reducing anxiety, improving medication compliance and social competency, but stated that 
further well-designed trials are needed [11].   
Our prospective service evaluation explores the effectiveness of a treatment for patients with 
epilepsy based on the Acceptance and Commitment Therapy (ACT) approach.  The general aim of 
ACT is to increase psychological flexibility (i.e. our ability to engage in valued behaviours while 
experiencing difficult thoughts, emotions, or sensations).  The approach incorporates mindfulness 
and behaviour change processes. The treatment was supported by a patient workbook and offered 
to a large consecutive series of patients by a single psychotherapist.  The intervention focused 
especially on anxiety, depression, lack of acceptance of the epilepsy diagnosis, emotional difficulties, 
e.g. guilt and shame, interpersonal and memory problems.  Apart from providing information 
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required for group size calculations of a future randomised study, this service evaluation was 
intended to explore how effective this particular intervention may be if it is offered to patients 
treated routinely in a clinical epilepsy service in which neurologists, neuropsychologists and epilepsy 
specialist nurses are able to refer patients without restriction.   
2. Material and methods 
2.1 Subjects and recruitment 
Patients with emotional problems relating to their refractory epilepsy were identified and referred 
by Neurology Consultants, Neuropsychologists and Epilepsy Nurses working at the Sheffield Teaching 
Hospitals NHS Foundation Trust in Sheffield, UK. The therapy was delivered in a hospital outpatient 
setting. Patients were sent self-report questionnaires (see below) as a way of opting in to therapy. 
The same questionnaire was sent out by a member of staff not involved in the delivery of the 
treatment immediately after therapy ended and again after 6 months post therapy.   
2.2 Therapeutic intervention 
2.2.1 Structure of the intervention 
Treatment consisted of an initial one and a half hour assessment followed by 6-20 follow-up 
appointments. Sessions were arranged on a weekly or fortnightly basis. Therapy was offered on a 
one-to-one basis. However, if the patient wished for a family member or friend to accompany them 
to their initial appointment or occasional subsequent appointments this was welcomed.  Therapy 
was delivered by a Cognitive Behavioural Psychotherapist with training in ACT. An exemplary case 
formulation is provided as supplementary web-content.  
 
2.2.2 Assessment session  
The assessment was aimed at identifying what the patient perceived as the main problems relating 
to their diagnosis of epilepsy.  This was placed within the ACT formulation.  The ACT formulation 
ĨŽĐƵƐĞƐŽŶŚŽǁƚŚĞƉĂƚŝĞŶƚ ?ƐƉĂƐƚĂŶĚĐƵƌƌĞŶƚůŝĨĞĐŽŶƚĞǆƚĨƵŶĐƚŝŽŶƚŽŵĂŝŶƚĂŝŶƚŚĞŝƌŽŶ-going 
ƐƚƌƵŐŐůĞǁŝƚŚůŝĨĞ ?dŚĞ ?,ĞǆĂĨůĞǆ ? ?ƐĞĞ&ŝŐƵƌĞ ? ?ŝƐĂǀĞƌǇƵƐĞĨƵůƐŝǆ-component diagram, which aids 
assessment and formulation in ACT.  The six processes included in the diagram are conceptualised as 
ƉƌŽŵŽƚŝŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐƉƐǇĐŚŽůŽŐŝĐĂůĨůĞǆŝďŝůŝƚǇ ?ǇĨŽĐƵƐŝŶŐŽŶƚŚĞƐĞƉƌŽĐĞƐƐĞƐƚŚĞƚŚĞƌĂƉŝƐƚŝƐĂůĞƌƚ
ƚŽƚŚĞƉĂƚŝĞŶƚ ?ƐĞǆƉĞƌŝĞŶƚŝĂůĂǀŽŝĚĂŶĐĞ ?ĨĞĞůŝŶŐƐ ?ƚŚŽƵŐŚƚƐŵĞ ŽƌŝĞƐŽƌƐĞŶƐĂƚŝŽŶƐǁŚŝĐŚƚŚĞƉĂƚŝĞŶƚ
is unwilling to endure); cognitive fusion (thoughts and language which the patient buys into to the 
ƉŽŝŶƚǁŚĞƌĞƚŚĞŝƌĂĐƚŝŽŶƐĂƌĞĐŽŶƚƌŽůůĞĚďǇƚŚĞŝƌƉĞƌĐĞƉƚŝŽŶŽĨǁŚŽƚŚĞǇĂƌĞĂŶĚǁŚŽƚŚĞǇ ?ƐŚŽƵůĚ ?
be); and loss of life direction (loosing sight of what the patient wants his or her life to really stand for 
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ŝŶƚŚĞƉƌĞƐĞŶƚ ?ĞǆĐĞƐƐŝǀĞĐŽŶĐĞƌŶƐĂďŽƵƚƚŚĞƉĂƐƚĂŶĚƚŚĞĨƵƚƵƌĞ ? ?dŚĞƉĂƚŝĞŶƚ ?ƐĂŐƌĞĞŵĞŶƚǁŝƚŚƚŚĞ
emerging formulation was always sought, and this formulation shaped the subsequent intervention. 
The assessment session also included the provision of psycho-education about the ACT model [12].  
This and an open, accepting, listening approach to the patient were intended to build rapport at this 
ĞĂƌůǇƐƚĂŐĞŽĨƚŚĞƚƌĞĂƚŵĞŶƚƉƌŽĐĞƐƐĂŶĚƚŽĂƐƐĞƐƐƚŚĞƉĂƚŝĞŶƚ ?ƐŵŽƚŝǀĂƚŝŽŶĨŽƌĨƵƌƚŚĞƌƚƌĞĂƚŵĞŶƚ ?
Once the patient understood the ACT model the session began to outline the treatment goals. 
Treatment goals were characterised more clearly in the follow-up sessions. Table 1 provides an 
overview of the six components and typical problems addressed by ACT. 
_____________________________Insert Figure 1 here_____________________________ 
2.2.3 Workbook   
During the first or second follow-up session, patients were given a copy of the workbook 
 “hŶĚĞƌƐƚĂŶĚŝŶŐƉŝůĞƉƐǇ ? WƐǇĐŚŽƚŚĞƌĂƉĞƵƚŝĐƉƉƌŽĂĐŚ ?to reinforce concepts and strategies 
learned in the therapy and provide self-help resources and worksheets for exercises [13].  The 
workbook is a 124-page illustrated brochure, which offers patients with epilepsy information about 
their condition and some of the commonest problems addressed by psychological treatment: 
anxiety, depression and concerns about memory failures. The self-help materials include, amongst 
others, a weekly activity schedule, thought record, valued directions worksheet, willingness and 
action plan worksheet, goal-setting worksheet, problem solving worksheet, building a 
compassionate image exercise, compassionate letter writing exercise, seizure, sleep, and eating 
diary, materials for the practice of cue controlled breathing, progressive muscle relaxation, mindful 
awareness, mindfulness in daily life, loving-kindness meditation, visualisation techniques, body scan 
exercise, grounding techniques, strategies for dealing with emotions, and more. 
2.2.4 Subsequent sessions  
In the follow-ƵƉƐĞƐƐŝŽŶƐ ?ƚŚĞƉĂƚŝĞŶƚ ?ƐƚƌĞĂƚŵĞŶƚŐŽĂůƐǁĞƌĞŝŶŝƚŝĂůůǇĐůĂƌŝĨŝĞĚĨƵƌƚŚĞƌ ?dŚĞǀĂůƵĞƐ
component in ACT steers the patient towards a reflection on what they really want for their lives.  It 
was considered important to spend time exploring thĞƉĂƚŝĞŶƚ ?ƐŵŽƐƚŝŵƉŽƌƚĂŶƚǀĂůƵĞƐƉƌŝŽƌƚŽŐŽĂů-
setting using ACT worksheets such as Valued Directions or Life Compass [13].   
Since all six components of ACT are interconnected, explicit reference was made to them whenever 
they were touched upon in therapy. Patients were given homework at the end of each session (eg. 
values-led exposure to enhance commitment to action along with Mindfulness exercises to promote 
acceptance and self-compassion).  Homework was reviewed at the beginning of the subsequent 
session and discussed with the patient with particular reference to their therapy goals and their 
proclaimed values. If anything got in the way of the patient being able to commit to their goals, this 
was discussed and worked on.    
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In addition the overall aim of ACT was re-emphasised in every session.  Mindfulness practice was 
taught as a way of helping the patient to open up to all emotions, memories and thoughts. Patients 
were taught to practice being more fully present to ordinary daily experiences without judgement.  
They were encouraged to practice meditation and self-compassion exercises, e.g. compassionate 
letter-writing, Compassionate Image (creating a compassionate/caring/nurturing image in the mind, 
characterised by the qualities of wisdom, strength, warmth and non-judgement), Safe Place 
(spending a few moments during the day thinking of and visualising a safe place to feel calmer and 
more relaxed), instructions for all of which were included in the workbook.  If the therapist noticed 
that the patient was fusing with language (getting overwhelmed by unhelpful thoughts or words), 
attention was drawn to the impact this was likely to be having on the patient.  Metaphors, both 
verbal and visual were used throughout therapy Metaphors are an important resource in ACT and 
are used to help reinforce relevant components of the treatment and to develop and normalise the 
ƉĂƚŝĞŶƚ ?ƐƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŝƌĚŝĨĨŝĐƵůƚŝĞƐ ?ǀĞƌǇƐĞƐƐŝŽŶĞŶĚĞĚǁŝƚŚƚŚĞĨŽƌŵƵůĂƚŝŽŶŽĨĂƉůĂŶĨŽƌ
the following week. 
_____________________________Insert Table 1 here_____________________________ 
2.2.5 End of therapy  
Patients were made aware that they could attend up to a maximum of 20 sessions.  Therapy process 
was reviewed at intervals of four weeks.  Therapy endings were always mutually agreed.  
An illustrative treatment report of a typical case is offered as web content (insert details of link to 
supplementary web content here). 
2.3 Outcome measures 
2.3.1 Short Form  ? 12 Health Survey Version 2 (SF-12v2)   
SF-12v2 is a 12-item self-report measure of health-related quality of life, adapted from the original 
SF-36 questionnaire [14]. It assesses eight dimensions of HRQoL over a 4-week recall period, 
including physical functioning (2 items), role limitation-physical (2 items), bodily pain (1 item), 
general health (1 item), vitality (1 item), social functioning (1 item), role limitation-emotional (2 
items), and mental health (2 items). These can be further summarised into a Physical Component 
Summary Scale (PCS) and Mental Health Component Summary Scale (MCS). The SF-12v2 is has been 
found a valid and a reliable substitute for the SF-36 [15, 16]. 
Individual items on the SF-12v2 were re-coded and combined into the eight subscales. Raw data 
have been transformed into final 0-100 scores and combined into the component summary sales. 
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Higher scores represent better quality of life. The component summary scales were assessed for 
ŝŶƚĞƌŶĂůĐŽŶƐŝƐƚĞŶĐǇƌĞůŝĂďŝůŝƚǇƵƐŝŶŐƌŽŶďĂĐŚ ?ƐĂůƉŚĂ ?W^ɲ = 0.81; MCS ɲ = 0.71). Subjects with 
missing data on any of the subscales were excluded from the analyses. 
The raw SF-12 data can be transformed into a six-dimensional classification of health state, the SF-
6D, which allows using the SF-12 in economic evaluations of health-related interventions. The SF-6D 
ŚĞĂůƚŚŝŶĚĞǆŝƐĂŶƵŵďĞƌƌĂŶŐŝŶŐĨƌŽŵ ? ? “ŚĞĂůƚŚ ? ?ƚŽ ? ? “ĚĞĂƚŚ ?ƚŚĂƚĐĂŶďĞƵƐĞĚƚŽĐĂůĐƵůĂƚĞ
quality-adjusted life year (QALY) gains associated with an intervention. 
2.3.2 Generalised Anxiety Disorder (GAD-7) Scale 
The GAD-7 is a 7-item self-report anxiety questionnaire, assessing anxiety symptoms experienced 
over the course of the past two weeks [17]. The reliability and validity of the GAD-7 have been 
tested and supported by a number of studies in both the general population and patients with 
psychopathology [18] [19, 20]. The GAD-7 has been validated by significant positive correlations with 
a number of anxiety measures, including the Hamilton Anxiety Scale, Beck Anxiety Inventory and the 
anxiety sub-scale of Symptom Checklist-90 [17, 21] and it has previously been used as a screening 
tool in epilepsy [22].  
The seven items of the GAD-7 were combined to produce a total score (higher score reflects higher 
anxiety levels). The internal consistency reliability of the total score in our sample was acceptable (ɲ 
= .78). Where one item was missing, a median replacement method was employed. Subjects with 
more than one item missing were not included in the analyses.  
2.3.3 Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)  
The NDDI-E is a 6-item inventory developed to detect depression in patients with epilepsy. The six 
items represent common symptoms of depression experienced in the past two weeks that can be 
differentiated from adverse effects of anti-epileptic drugs [23]. Higher scores on the NDDI-E indicate 
greater impairment. The inventory was found to have good internal consistency and test-retest 
reliability [23, 24]. A score of more than 15 on the NDDI-E was found to have 90% specificity, 81% 
sensitivity and a predictive value of 0.62 for a diagnosis of major depression [23] and NDDI-E was 
also found to have significant positive correlation with another screening tool for depression, the 
Patient Health Questionnaire [24].  
Responses to the six items on the NDDI-E were summed into a total score and assessed for internal 
consistency reliability (ɲ = 0.78). Missing data on one item were replaced by the median of the 
completed items. Subjects with more than one item missing were excluded from the analyses.  
2.3.4 Work and Social Adjustment Scale (WSAS)  
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The WSAS is a 5-item measure of impaired functioning attributable to a particular problem or 
disease [25]. The scale assesses impairment in five areas of work and social activities, including work, 
home management, social leisure activities, private leisure activities, and family and relationships, 
with higher values indicating greater impairment. The WSAS has been established as a valid, reliable 
and sensitive measure in a number of different disorders, including depression, anxiety, OCD, phobic 
disorders, or insomnia and it has proven a sensitive measure in a number of studies of patients with 
psychogenic non-epileptic seizures [25-29]. 
The five item scores were combined into a total score, which was found to have acceptable internal 
consistency reliability (ɲ = 0.79). Missing values on one item were replaced by median scores of the 
completed items. Cases with more than one item missing were excluded from the analyses.  
2.3.5 Rosenberg Self-Esteem Scale (RSES) 
The RSES is a 10-item measure of self-esteem measuring both positive and negative feelings about 
the self [30]. The scale is uni-dimensional and produces a single total score, with higher values 
representing higher self-esteem.  The RSES is a well-established scale that has been used and 
validated by a number of studies [31-33]. 
Responses to the RSES were combined into a total score and assessed for internal consistency 
reliability (ɲ = 0.87). Median replacement was used in cases with one missing item on the RSES. 
Cases with more than one item missing were excluded from the analyses. 
2.3.6 Demographic questionnaire 
A simple demographic questionnaire was developed for the study to collect information about 
gender, marital status, employment status, education level, seizure duration and frequency. 
2.3.7 Seizure frequency  
Seizure frequency expressed as the number of seizures per one month was self-reported by patients 
in the demographic questionnaire. Patients who reported zero seizures in the past month were 
ĐůĂƐƐĞĚĂƐ ?ƐĞŝǌƵƌĞĨƌĞĞ ? ?
2.4 Cost-effectiveness 
The estimation of cost-effectiveness of the therapy was based on the calculation of quality-adjusted 
life year (QALY) gains associated with the therapy and the cost of the therapy. QALYs were 
calculated using the SF-6D health index derived from the original SF-12v2 data [34].  The number of 
QALYs gained by the therapy was obtained by subtracting the mean post-therapy (T1) from the 
mean baseline (T0) SF-6D index and multiplying the resulting score by the number of years for which 
the improvement was expected to last.  
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The direct therapy costs were estimated for one hour of treatment. This figure was obtained by 
following a procedure described in a similar study [35]: The midpoint of the gross annual salary for 
Band 7 salary scale (£36,193) plus 25% for employment on-cost provisions is £45,241 ( ?57,123; 
$72,984). This figure was divided by 52 (weeks) and 37.5 (hours), and time for keeping notes, 
supervision, and other related activities was added to the time spent with patients face to face at a 
ratio of 0.67:1. The resulting cost was £38.75 ( ?49; $63) per one hour of therapy. This was multiplied 
by the mean number of therapy sessions attended by the patients of the study. The resulting cost of 
the therapy was then divided by the number of QALYs gained to get an indication of the cost-
effectiveness of the therapy (cost/QALY). 
2.5 Statistical analyses 
Data were analysed using SPSS (version 21; SPSS Inc., Chicago, IL, U.S.A.). Distribution of scores was 
assessed for normality using the Shapiro-Wilk test. As scores on the WSAS, GAD-7, RSES, and most of 
the SF-12 sub-scales were non-normally distributed (ps < .001), non-parametric tests were used 
throughout. Data at baseline (T0) and after therapy (T1), as well as after therapy (T1) and at follow-
up (T2) were compared using paired-samples Wilcoxon Signed-Ranks Test. Bonferroni correction was 
applied to the T0/T1 and T1/T2 comparisons. As there were 15 comparisons in each analysis, 
Bonferroni adjusted p-values of <0.003 were considered statistically significant (0.05/15).  Effect 
sizes (r) were calculated based on the formula for Wilcoxon Signed-Ranks Test [36]. According to the 
ŽŚĞŶ ?ƐĐƌŝƚĞƌŝĂ ?ĂŶĞĨĨĞĐƚƐŝǌĞŽĨ ? ? ?ǁĂƐĐŽŶƐŝĚĞƌĞĚ ?ƐŵĂůů ? ? ? ? ?ƌĞƉƌĞƐĞŶƚĞĚĂ ?ŵĞĚŝƵŵ ?ĞĨĨĞĐƚƐŝǌĞ
ĂŶĚ ? ? ?ǁĂƐĐŽŶƐŝĚĞƌĞĚ ?ůĂƌŐĞ ?[37]. 
2.6 Regulatory approval 
The data, which form the basis of this report, were collected as part of the routine evaluation of our 
psychotherapy service required by the funders of the service. The service evaluation was approved 
by the Clinical Effectiveness Unit of Sheffield Teaching Hospitals NHS Foundation Trust and 
conducted in full compliance with the Governance Regulations of this organisation. 
3. Results 
3.1 Subjects 
A total of 159 patients completed the initial set of questionnaires. Of these, 60 patients completed 
both the baseline (T0) and post-therapy (T1) questionnaires and were included in the analyses. A 
further 41 patients returned the follow-up (T2) questionnaires. Three of these patients did not 
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return the post-therapy (T1) questionnaires and the T1 versus T2 comparisons were therefore 
performed using data from the 38 patients who had returned data at both time points.  
3.2 Demographic and clinical characteristics 
Of the 60 patients who completed T0 and T1 questionnaires, 76.7% were female (N = 46). The 
median age of the group was 40 years (age range 19  ? 75). At the time of the therapeutic treatment, 
 ? ? ? ?A?ŽĨƚŚĞƉĂƚŝĞŶƚƐǁĞƌĞ ?ĞĐŽŶŽŵŝĐĂůůǇŝŶĂĐƚŝǀĞ ? ?ƵŶĞŵƉůŽǇ Ěor retired), while 42.9% of the 
ƉĂƚŝĞŶƚƐǁĞƌĞ ?ĞĐŽŶŽŵŝĐĂůůǇĂĐƚŝǀĞ ? ?ĞŵƉůŽǇĞĚĨƵůů-time or part-time or in full-time education). More 
information about the demographic characteristics of the group is detailed in Table 2. 
_____________________________Insert Table 2 here_____________________________ 
dŚĞƉĂƚŝĞŶƚƐ ?ĐůŝŶŝĐĂůĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐĂƌĞƐƵŵŵĂƌŝƐĞĚŝŶdĂďůĞ ? ?dŚĞŵĞĂŶŶƵŵďĞƌŽĨƚŚĞƌĂƉǇ
appointments attended was 11.5 (S.D. = 9.6). 
_____________________________Insert Table 3 here_____________________________ 
3.3 Comparisons of baseline (T0) versus post-therapy (T1) 
Psychotherapy was associated with significant improvements on most of the outcome measures at 
T1 (Table 4).  
A significant improvement was found on most of the eight dimensions of the SF-12. Only the 
improvements on the physical functioning sub-scale and the physical health summary scale of the 
SF-12 were not significant.  
Therapy was associated with significant improvement of work and social functioning (WSAS score), 
as well as a decrease in anxiety and depression (as measured by the GAD-7 and NDDI-E).  
We also observed a ƐŝŐŶŝĨŝĐĂŶƚŝŵƉƌŽǀĞŵĞŶƚŝŶƚŚĞƉĂƚŝĞŶƚƐ ?ƐĞůĨ-esteem, reflected by a significant 
increase on the RSES.  
There was a change in the median seizure frequency, which approached significance (p = .006).  
Effect size calculations revealed that the effect sizes of the changes from T0 to T1 that reached 
significance ranged from medium to large (see Table 4). 
_____________________________Insert Table 4 here_____________________________ 
Improvement was further explored for the psychological outcome measures that showed significant 
change, namely the SF-12, WSAS, GAD-7, NDDI-E, and RSES.  Overall, 73.3% of the patients improved 
by at least 1 S.D. on at least one of the five measures, 53.3% improved on two or more measures, 
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and 35.0% improved on three or more measures. Deterioration by at least 1 S.D. on one or more of 
the measures was found in 21.7% of the patients (see Table 5 for more information).  
_____________________________Insert Table 5 here_____________________________ 
As there was a large variability in the seizure frequency data. Table 6 shows the percentage 
improvement in seizure frequency.  
_____________________________Insert Table 6 here_____________________________ 
 
3.4 Comparisons post-therapy (T1) versus follow-up (T2) 
There was no significant change in any of the outcome measures between T1 and T2, suggesting that 
the immediate benefits of the psychotherapeutic intervention were sustained for at least six months 
after treatment (see Table 4 for further details).  
3.5 Cost-effectiveness 
The mean baseline (T0) SF-6D index was 0.57 and the mean SF-6D index after therapy (T1) was 0.65 
(difference = 0.08). As the cost of one hour of therapy was estimated to be £38.75 and the mean 
number of therapy sessions attended was 11.5, the cost of the therapy was approximately £445.6 
( ?563; $718). Given the 0.08 QALY gain and assuming that the benefits of the therapy would last for 
six months, the resulting cost/QALY associated with the therapy was £11,140 ( ? ? ? ? ? ? ? ?$18,016). If 
the benefits persisted for one year, the cost would be reduced to £5,570/QALY ( ?7,039; $8,979).  
4. Discussion 
Epilepsy is a complex condition. It is associated with a wide range of comorbidities, and psychosocial 
ĐŽŵƉůŝĐĂƚŝŽŶƐ ?ǁŚŝĐŚŵĂǇďĞŵŽƌĞĚŝƐĂďůŝŶŐĂŶĚĚĞƚƌŝŵĞŶƚĂůƚŽƚŚĞƉĂƚŝĞŶƚƐ ?ƋƵĂůŝƚǇŽĨůŝĨĞƚŚĂŶƚŚĞ
seizures itself. A number of studies have highlighted the psychosocial impacts of epilepsy and 
emphasised the need for treatments addressing the full spectrum of problems associated with the 
disorder, rather than focus purely on seizure reduction [3, 4, 38, 39]. However, there is a lack of 
accessible and cost-effective psychological and behavioural interventions that are supported by high 
quality empirical evidence. This is likely to be one of the reasons why this treatment need therefore 
remains largely unmet [9, 11].  
The aim of the current service evaluation was to explore the effectiveness of a psychotherapy 
programme based on the ACT approach and to provide information about effect sizes that could 
inform the design of future RCTs. The results of the evaluation show that the therapy had significant 
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medium to large effects on depression, anxiety, quality of life, work and social adjustment, and self-
esteem, which were sustained several months after therapy. Given the adjustments for multiple 
comparisons that were made on the significance levels, the results of this evaluation provide a 
conservative estimate of the effects of the intervention. 
The observed improvements of depression and anxiety are particularly encouraging, as depression 
and anxiety are common comorbidities with a complex, bi-directional relationship with epilepsy 
which often complicate the management of the disorder [39, 40]. Appropriate treatment of 
comorbid mood disorders has been suggested to have potentially important benefits for both 
seizure management and improved quality of life [39]. 
Significant improvement was found in most aspects of quality of life (measured by the SF-12) 
following the therapy, as well as on the Work and Social Adjustment scale. This finding is concordant 
with existing evidence from a small number of controlled studies of cognitive behavioural therapy 
and ACT for epilepsy. Martinovic et al. reported both significant reduction of depressive symptoms 
and improved quality of life in adolescent patients receiving a CBT intervention, compared to a 
control group [41], a CBT intervention was also effective in improving quality of life in a small RCT 
from Hong Kong [42], and two small-scale RCTs by Lundgren et al. showed significant improvements 
in quality of life following a short-term ACT treatment [43, 44]. 
Whilst scores on all the mental health related sub-scales of the SF-12 were significantly better after 
therapy, no change was found on the physical health component summary scale and the physical 
functioning sub-scale. This may suggest that our therapeutic approach, which was primarily focused 
on emotional, interpersonal and cognitive difficulties, was indeed more effective in improving the 
emotional and social aspects of HRQoL rather than physical functioning. Having said that, all the 
other physical sub-scales of the SF-12 including general health, bodily pain and role limitations due 
to physical health did show significant improvement after treatment. It is possible that the particular 
issues captured by the physical functioning sub-scale, which include physical activities such as 
 ?ƉƵƐŚŝŶŐĂǀĂĐƵƵŵ ? ?ƉůĂǇŝŶŐŐŽůĨŽƌĐůŝŵďŝŶŐƵƉƚŚĞƐƚĂŝƌƐŵĂǇŶŽƚďĞĐŽŵƉƌŽŵŝƐĞĚŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
epilepsy or may not be amenable to change by psychotherapy alone. This interpretation would be 
supported by other studies that failed to find any effects of psychotherapy on the physical 
functioning sub-scale of the SF-36 [35].  
In addition to the positive effects on depression, anxiety and overall quality of life, which were the 
focus of the psychotherapy, we also found a significant improvement in self-esteem. Self-esteem is 
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often low in patients with epilepsy and could play an important role in the psychosocial adjustment 
to epilepsy, especially in relation to the perceived stigma associated with the disorder [6].  
The change in median seizure frequency following therapy only approached significance. Closer 
examination of the changes in seizure frequency showed that although 37.2% of patients reported a 
more than 50% reduction in seizure frequency, there were more patients (39.5%) who experienced a 
smaller than 50% improvement or no change at all.  This finding is in contrast with the findings of the 
studies by Lundgren et al. [43, 44] who reported a significant decrease in seizure frequency as a 
result of ACT psychotherapeutic treatment. However, the overall evidence for effectiveness of 
psychological interventions for reducing seizures is mixed [11], and it is important to emphasise that 
the focus of the therapeutic approach used in our study was on the psychosocial issues associated 
with epilepsy rather than reduction of seizure frequency per se.  
The estimated cost-effectiveness of the therapy suggests that our psychotherapy programme is 
relatively inexpensive and far below the National Institute for Health and Clinical Excellence cost-
effectiveness threshold of £25,000 - £35,000 [45].  
4.1 Limitations 
The Cochrane review of psychological treatments for epilepsy mentioned above stated that more 
 “ŚŝŐŚƋƵĂůŝƚǇĞǀŝĚĞŶĐĞ ?ĐŽŶĨŽƌŵŝŶŐƚŽƚŚĞďŝŽŵĞĚŝĐĂůŵŽĚĞůŝƐƌĞƋƵŝƌĞĚ ? “,ŝŐŚƋƵĂůŝƚǇĞǀŝĚĞŶĐĞ ?
usually means double-blind randomised controlled trials (RCTs). Whilst therapists in psychotherapy 
cannot be blinded, and there are significant study design challenges relating to the control condition 
of psychological RCTs, studies in many areas have demonstrated that psychotherapy RCTs are 
feasible [46-48]. This means that there is no reason why psychological treatments for patients with 
epilepsy could not be conducted in this way. Having said that, there are issues with the 
generalisation of the results of psychotherapy RCTs, which may not apply in the same way to RCTs of 
simpler interventions, for instance the use of a new drug.  Patients undergoing psychological 
treatment have to make a considerable investment in time, hope and energy to complete a course 
of treatment. Taking part in a psychotherapy RCT is likely to be particularly difficult and likely to 
require a high level of motivation on the part of the patient. This means that the patients taking part 
in psychotherapy RCTs may be quite different from those seen in routine clinical practice and 
referred for psychological treatment. The lack of a randomisation procedure or exclusion criteria in 
the current service evaluation means that the results may be more readily generalisable to patients 
routinely seen in neurological practice. Nevertheless, the uncontrolled, exploratory design of the 
study is an obvious limitation of our evaluation and makes it difficult to determine with certainty 
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that the psychotherapy was the sole cause of the observed improvements in the psychological 
measures.  
All of the psychological treatment in this service evaluation was delivered by a single therapist. 
Whilst this and the fact that the therapeutic approach was supported by a manual means that the 
treatment offered was relatively homogeneous, and the treatment effect sizes seen in our service 
evaluation were similar to the those in other studies using a similar therapeutic approach [49], the 
fact that only one therapist was involved here means that it is impossible, at this stage, to separate 
between therapist and treatment effects. 
In addition, there are limitations related to the reliance on self-report measures, which are 
subjective and prone to a range of biases, such as the social desirability bias or a tendency to 
respond in a way that may be viewed favourably by the researcher or the therapist.   
5. Conclusions 
Bearing in mind these limitations, this service evaluation suggests that the described psychotherapy 
programme, based on the ACT approach, has medium to large positive effects on depression and 
anxiety, quality of life, adjustment and self-esteem. These positive effects were observed 
immediately after treatment and sustained for at least six months beyond the end of therapy. 
Benefits were associated with relatively low costs. These results are promising and suggest that a 
randomised controlled trial of the psychotherapy programme is justified.  
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9. Figures 
&ŝŐƵƌĞ ? ? ?,ĞǆĂĨůĞǆ ? ? schematic representation of the six main components of ACT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contact with the 
Present Moment 
Learning to observe 
thoughts, feelings, 
behaviours and 
sensations so as to act 
effectively in the 
present moment. 
Self as Context 
Being able to recognise 
thoughts & feelings  
while knowing that I 
am distinct from them 
and therefore I am 
part of a bigger 
picture.  
 
Defusion 
Recognising thoughts, 
feelings, memories, 
sensations just for 
what they are so as to 
reduce their influence 
on  behaviour since it 
is entanglement with 
them that causes the 
problem.  
Acceptance 
Letting go of the need 
to control. Being 
willing to experience all 
thoughts, feelings and 
sensations  as they 
happen.  
Committed Action 
Identifying the 
actions necessary to 
put  values into 
practice. 
Wholehearted 
commitment to 
ƚŚĞƐĞ ?ǀĂůƵĞĚ ?
actions. 
Values 
Being clear about 
values and using 
them to influence my 
life directions  
 
Psychological 
Flexibility 
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10. Tables 
Table 1. The six components of ACT  
Six components of ACT Typical core problems  
Contact with the present moment Absorbed in the past or the future  
Acceptance and willingness as an alternative agenda Experiential avoidance 
Self as context Self as content 
Cognitive defusion Cognitive fusion 
Commitment & behaviour change processes Inaction or ineffective action 
Values-guided action Disconnection from values 
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Table 2. Demographic Information 
 
Variable N Mean (S.D.)/Percent 
Full-time Education (years) 51 12.77 (4.45) 
Employment Status Total 56  
     Full-time 14 25.0% 
     Part-time 8 14.3% 
     Unemployed 21 37.5% 
     Student  2 3.6% 
     Retired 11 19.6% 
Marital Status Total 58  
     Single 18 31.0% 
     Married 28 48.3% 
     Live with partner 4 6.9% 
     Divorced/Separated 8 13.8% 
     Widowed 0 0% 
Note. S.D. = standard deviation. 
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Table 3. Clinical variables 
 
Variable N Mean (SD)/Median (IQR)/Percent 
Epilepsy duration (years) 56 14.9 (14.8) 
Median seizure frequency (seizures/month) 42 2.00 (3.40) 
Type of epileptic seizures   
     Primary generalised seizures   
          Tonic-clonic seizures 9 15.0% 
          Absence seizures 3 5.0% 
          Myoclonic seizures 5 8.3% 
     Partial   
           Simple or complex partial seizures 20 33.3% 
           Partial seizures with secondary generalisation 10 16.7% 
    Unknown 17 28.3% 
Note. S.D. = standard deviation. 
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Table 4. Comparison of median scores of the main outcome measures at baseline (T0), post-therapy 
(T1), and at follow-up (T2) 
 
Outcome Measure Score at T0 
M (IQR) 
Score at T1 
M (IQR) 
(N=60) 
 
Score at T2 
M (IQR) 
(N=38) 
P for T0/ T1 
comparison 
Effect 
size (r) 
P for T1/T2 
comparison 
SF-12       
 Mental Health Summary  25.89 (17.49) 38.39 (18.11) 34.06 (19.71) <.001 .46 n.s. 
 Physical Health Summary  43.33 (16.60) 48.32 (16.29) 45.93 (19.71) n.s. .19 n.s. 
    Physical Functioning 47.88 (17.18) 47.88 (25.77) 47.88 (23.62) n.s. .06 n.s. 
    Role Limitation  ? Physical 34.14 (14.97) 38.75 (18.42) 38.75 (23.03) .001 .31 n.s. 
    Bodily Pain 47.25 (30.57) 47.25  (20.38) 47.25 (30.57) .002 .29 n.s. 
    General Health 29.65 (15.09) 44.74 (15.09) 29.65 (15.09) .001 .29 n.s. 
    Vitality 37.69 (20.13) 47.75 (10.06) 37.69 (10.06) <.001 .33 n.s. 
    Social Functioning 26.27 (10.10) 36.37 (30.30) 36.37 (30.30) <.001 .35 n.s. 
    Role Limitation - Emotional 22.53 (16.77) 33.71 (22.37) 33.71 (22.37) .001 .32 n.s. 
    Mental Health 27.97 (9.14) 40.16 (12.19) 40.16 (12.19) <.001 .49 n.s. 
WSAS 22.50 (12.00) 12.75 (12.63) 15.00 (19.00) <.001 .50 n.s. 
GAD-7 15.00 (6.25) 7.00 (12.25) 9.00 (9.25) <.001 .47 n.s. 
NDDI-E 19.00 (4.25) 15.50 (7.00) 15.00 (4.00) <.001 .42 n.s. 
RSES 12.00 (8.00) 15.00 (9.00) 14.00 (6.00) <.001 .35 n.s. 
Seizure Frequency 2.00 (3.40) 1.00 (3.16) 2.00 (2.50) n.s. .30 n.s. 
Note. M = median; IQR = interquartile range; n.s. = non-significant difference. 
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Table 5. Improvement and deterioration on the outcome measures that showed significant change 
from baseline (T0) to post-therapy (T1) 
 
Outcome Measure N (100%) N Improved by A? 1 S.D. (%) N Deteriorated by A? ?^ ? ? ?A? ? 
SF-12 MHS (S.D. = 11.14) 47 21 (44.7%) 2 (4.3%) 
WSAS (S.D. = 8.77) 52 25 (48.1%) 2 (3.9%) 
GAD-7 (S.D. = 4.49) 54 31 (57.4%) 6 (11.1%) 
NDDI-E (S.D. = 3.19) 54 26 (48.2%) 3 (5.6%) 
RSES (S.D. = 5.94) 51 19 (37.3%) 4 (7.8%) 
Note. S.D. = standard deviation from the mean.  
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Table 6. Improvement and deterioration of seizure frequency from T0 to T1. 
 
Change N % 
Total 43 100% 
     100% Improvement (seizure-free) 4 9.3% 
     >50% Improvement  16 37.2% 
     No change  (A?50% improvement to A?50% deterioration) 17 39.5% 
     >50% Deterioration 1 2.3% 
     >100% Deterioration 5 11.6% 
 
 
 
 
